NT Pharma, a pharmaceutical company in China, agreed to acquire a 40% stake in Kangchen, which focuses on the development of special drugs, for $51m. NT Pharma Group claims that the deal will bring about $4.8m in net profit. Proceeds will be used to pay the debt and embark on the partial redemption of the CPS, which is due on June 30, 2020.